Shots:

• The BLA is based on P-I TRANSCEND NHL 001 study assessing Lisocabtagene Maraleucel (liso-cel) in 268 patients with r/r B-cell NHL including DLBCL- HGL- PMBCL and Grade 3B FL
• The P-I TRANSCEND NHL 001 study is the largest study of CD19-directed CAR T cells supporting the BLA submission. Liso-cel has received FDA’s BT & RMAT designation for r/r large B-cell NHL and PRIME designation for r/r DLBCL
• Liso-cel is CART-cell therapy targeting CD19 with a defined composition of CD8+ & CD4+ CAR T cells to treat r/r B-cell NHL prior treated with 2L+ therapies with its anticipated PDUFA date as Aug 17- 2020

Click here ­to­ read full press release/ article 

 Ref: BMS | Image: BMS